1. Home
  2. KE vs ALT Comparison

KE vs ALT Comparison

Compare KE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimball Electronics Inc.

KE

Kimball Electronics Inc.

HOLD

Current Price

$26.17

Market Cap

564.2M

Sector

Technology

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.27

Market Cap

573.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KE
ALT
Founded
1961
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
564.2M
573.8M
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
KE
ALT
Price
$26.17
$3.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$28.00
$17.67
AVG Volume (30 Days)
206.6K
4.0M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
66.18
25.37
EPS
1.13
N/A
Revenue
$1,431,378,000.00
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.57
N/A
P/E Ratio
$22.16
N/A
Revenue Growth
N/A
105.00
52 Week Low
$21.60
$2.56
52 Week High
$33.19
$6.44

Technical Indicators

Market Signals
Indicator
KE
ALT
Relative Strength Index (RSI) 53.09 57.93
Support Level $23.42 $3.18
Resistance Level $26.85 $3.32
Average True Range (ATR) 0.70 0.15
MACD 0.17 0.02
Stochastic Oscillator 83.15 56.68

Price Performance

Historical Comparison
KE
ALT

About KE Kimball Electronics Inc.

Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: